The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Updated results of AUGMENT-101: revumenib in R/R KMT2Ar acute leukemia
Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, briefly discusses the updated results of the AUGMENT-101 study (NCT04065399) investigating the novel menin inhibitor revumenib in patients with relapsed/ refractory (R/R) KMT2A rearranged (KMT2Ar) acute leukemia. Revumenib was recently approved by the FDA for this subset of patients with acute myeloid leukemia (AML). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
AUGMENT-101 is a study that looks at a novel menin inhibitor called revumenib for patients with relapsed and refractory acute myeloid leukemia with a KMT2A rearrangement. And that’s the data that we presented yesterday in an oral abstract session showing the results in 97 patients with relapsed and refractory KMT2A rearranged acute leukemia where those patients had a very high overall response rate of about 64% and the rate of CR and CRh was about 23%...
AUGMENT-101 is a study that looks at a novel menin inhibitor called revumenib for patients with relapsed and refractory acute myeloid leukemia with a KMT2A rearrangement. And that’s the data that we presented yesterday in an oral abstract session showing the results in 97 patients with relapsed and refractory KMT2A rearranged acute leukemia where those patients had a very high overall response rate of about 64% and the rate of CR and CRh was about 23%. What’s most exciting about revumenib is that it was actually approved by the Food and Drug Administration on November 15th for the treatment of this subset of patients with AML.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Jazz Pharmaceuticals: Consultancy, Other: consulting fees; Daiichi Sankyo, Inc.: Consultancy, Other: consulting fees; Agios Pharmaceuticals: Consultancy, Other: consulting fees; Servier: Consultancy, Other: consulting fees; Abbvie: Consultancy, Other: consulting fees; Astellas Pharmaceuticals: Consultancy, Other: consulting fees; Celgene: Consultancy, Other: consulting fees; AstraZeneca: Consultancy, Other: consulting fees; Gilead: Consultancy, Other: consulting fees; Genentech: Consultancy, Other: consulting fees.
